atezolizumab,paclitaxel,gemcitabine,cisplatin
roche
['muc ,(-much)', 'vedo', 'docetaxel', 'nivolumab', 'methotrexate', 'pembro', 'atezo', ' vedo', 'cisplatin', 'sacituzumab', 'imvigor130', 'paclitaxel', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sacitu, govi', 'carboplatin', 'vinflunine', 'nivo', 'gemcitabine']
final os from ph 3 imvigor130: atezo + plt/gem vs pbo + plt/gem for 1l locally adv or muc #gu23 atezo + plt/gem vs pbo + plt/gem: os itt: hr 0.85, 95% ci 0.73, 1.00 next therapies: 33% vs 47% os cisplatin: hr 0.76, 95% ci 0.57, 1.01 os 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday